Biotechnology
Viking Therapeutics Moves Oral Obesity Drug Into Late-Stage Development
Company advances VKTX program as competition intensifies in the rapidly expanding weight-loss market Viking Therapeutics (VKTX) announced Wednesday that it...
Hims & Hers Shares Plunge as FDA Tightens Grip on Compounded GLP-1 Drugs
Regulatory crackdown and Novo Nordisk lawsuit rattle investors and reshape weight-loss drug landscape Shares of Hims & Hers Health (HIMS)...
Serina Therapeutics Advances Parkinson’s Program After Key FDA Green Light
IND clearance positions SER-252 for clinical progress in advanced Parkinson’s disease treatment Serina Therapeutics (SER) announced a significant regulatory milestone...
AI Is Already Transforming Drug Development—Just Not Where Investors Expected
While “AI-discovered” breakthrough medicines are still emerging, pharma is using AI today to cut costs, speed trials, and reduce regulatory...
GSK to Acquire RAPT Therapeutics for $2.2 Billion, Strengthening Its Immunology Pipeline
Deal delivers global rights to experimental food allergy therapy ozureprubart as GSK pursues growth under new CEO Luke Miels. Britain’s...
XTL Biopharmaceuticals Makes Bold Bet on Autism Breakthrough with NeuroNOS Acquisition
Transformative deal targets the biological roots of autism, opening a new frontier in disease-modifying therapy. XTL Biopharmaceuticals has taken a...
Alumis Breaks Out With Promising Psoriasis Data
Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026 Biotech stock Alumis (ALMS) surged more than 110%...
Ironwood Pharmaceuticals Lays Out Ambitious 2026 Outlook
Strong LINZESS growth, rising profitability, and pipeline progress underpin confidence despite pricing changes Ironwood Pharmaceuticals (IRWD) entered 2026 with a...
FDA Approves YARTEMLEA as First-Ever Treatment for TA-TMA
Omeros secures landmark approval for a life-saving therapy in adults and children following stem cell transplant The U.S. Food and...
Processa Pharmaceuticals Reports Promising Phase 2 Results for Breast Cancer Therapy
NGC-Cap shows enhanced cancer-killing exposure with comparable safety ahead of 2026 interim analysis Processa Pharmaceuticals (PCSA) provided a positive clinical...
